Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

ClinicalTrials.gov ID: NCT03761108

Public ClinicalTrials.gov record NCT03761108. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 9, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma

Study identification

NCT ID: NCT03761108
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Regeneron Pharmaceuticals; Industry
Enrollment: 387 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

Linvoseltamab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 22, 2019
Primary completion: Mar 29, 2033
Completion: Jun 15, 2033
Last update posted: Apr 19, 2026

2019 – 2033

United States locations

U.S. sites: 14
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
Sylvester Comprehensive Cancer Center	Miami	Florida	33136	Active, not recruiting
Moffitt Cancer Center - McKinley Drive	Tampa	Florida	33612	Recruiting
Emory University Hospital	Atlanta	Georgia	30322	Recruiting
Indiana University_Michigan Street	Indianapolis	Indiana	46202	Active, not recruiting
Norton Cancer Institute	Louisville	Kentucky	40207	Recruiting
C. S. Mott_University of Michigan	Ann Arbor	Michigan	48109	Active, not recruiting
Barbara Ann Karmanos Cancer Center	Detroit	Michigan	48201	Active, not recruiting
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08901	Active, not recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Recruiting
Columbia University Medical Center	New York	New York	10032	Active, not recruiting
Ohio State University James Cancer Hospital	Columbus	Ohio	43210	Recruiting
Oregon Health and Science University (OHSU) Marquam Hill Campus	Portland	Oregon	97239	Recruiting
University of Texas MD Anderson Clinic	Houston	Texas	77030	Active, not recruiting
Swedish Cancer Institute	Seattle	Washington	98104	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03761108, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 19, 2026 · Synced May 9, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03761108 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →